Having recently raised $6.1m in a funding round, Biotech company Pictor has now obtained CE mark for its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test.
The approval will enable the firm to market the antibody test in Europe and obtain regulatory approval in South East Asian markets.
Claimed to be the first of its kind, the PictArray SARS-CoV-2 ELISA antibody test is designed to separately identify antibodies from vaccines and Covid-19 infection in a single test.
